NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $73,363 | $58,465 | $33,641 | $23,137 |
| - Cash | $7,184 | $2,910 | $5,548 | $1,443 |
| + Debt | $347 | $10,232 | $8,397 | $6,577 |
| Enterprise Value | $66,526 | $65,787 | $36,490 | $28,271 |
| Revenue | $242 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $145 | $0 | $0 | -$1 |
| % Margin | 59.9% | – | – | – |
| EBITDA | -$5,847 | -$17,581 | -$5,512 | -$9,077 |
| % Margin | -2,416.1% | – | – | – |
| Net Income | -$5,890 | -$17,581 | -$5,512 | -$9,078 |
| % Margin | -2,433.9% | – | – | – |
| EPS Diluted | -0.27 | -0.98 | -0.34 | -0.86 |
| % Growth | 72.4% | -188.2% | 60.5% | – |
| Operating Cash Flow | -$2,891 | -$4,028 | -$3,480 | -$1,464 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2,891 | -$4,028 | -$3,480 | -$1,464 |